BIO vs MRK: fair value comparison
Bio-Rad Laboratories, Inc. and Merck & Co., Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BIO currently sits closer to the top of our discount ranking. BIO carries the stronger quality grade.
| BIO | MRK | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $330.01 | $143.93 |
| 12-month range | $256.55–$380.96 | $82.49–$149.86 |
| Sector rank | #91 of 113 Healthcare | #95 of 113 Healthcare |
| Quality grade | A | C |
| Leverage | Low | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BIO fair value analysis · MRK fair value analysis